Abcam and MEDx extend precision medicine strategic partnership
April 12 2021 - 5:00AM
Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science
reagents and tools, and MEDx Translational Medicine (MEDx),
formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a
company dedicated to developing companion diagnostics and precision
medicine, announced the extension of their strategic partnership to
include the co-development and commercialization of key companion
and in vitro diagnostic kits for MEDx to supply to the Chinese
market.
Nick Zhang, CEO of MEDx
commented: “China is embracing the arrival of
precision medicine, creating unprecedented opportunities for the
pharma and healthcare industry. This new collaboration expands our
strong relationship with Abcam and leverages their integrated
solutions to support the development of innovative diagnostic kits
from target validation to clinical trial testing.”
Under the terms of the agreement, the partners
will together define target product profiles that will support the
growth of precision diagnostic for selected indications in China.
Abcam will provide MEDx with access to the corresponding validated
specific antibodies from their pipeline and portfolio and will
co-create novel binders as required. MEDx will complete the
development of these into companion diagnostics and in vitro
diagnostic kits for wider commercialization.
Dr John Baker, SVP of Business
Development at Abcam said: “We are looking forward to
combining our end-to-end capabilities to identify and develop
high-quality recombinant monoclonal antibodies with MEDx’s
companion diagnostics development experience. We are excited to be
partnering with MEDx and supporting their commitment to accelerate
the development and marketing of precision medicine that can
positively impact people’s lives across China.”
This agreement builds on an existing
collaboration formed in 2018, which has delivered antibody
solutions designed specifically to support the development and
commercialization of several in vitro diagnostic reagents and kits
by MEDx that address key targets, including NY-ESO-1, Claudin 18.2,
HER2, Trop2, LAG-3 and CD73.
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam
identifies, develops, and distributes high-quality biological
reagents and tools that are crucial to research, drug discovery and
diagnostics. Working across the industry, the Company supports life
scientists to achieve their mission, faster.
Abcam partners with life science organizations
to co-create novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays,
Abcam is helping advance the global understanding of biology and
causes of disease, which enables new treatments and improved
health. The Company's pioneering data-sharing approach gives
scientists increased confidence in their results by providing
validation, user comments and peer-reviewed citations for its
110,000 products.
With 13 sites globally, many of Abcam's
1,500-strong team are located in the world's leading life science
research hubs, complementing a global network of services and
support.
To find out more, please
visit www.abcam.com and www.abcamplc.com.
About MEDx (Suzhou) Translational
Medicine
MEDx (Suzhou) Translational Medicine Co., Ltd
(simply MEDx) was founded in 2013, formerly known as QIAGEN
(Suzhou) Translational Medicine Co., Ltd. With comprehensive
technology platforms, high quality system, and strong IVD R&D
experience, MEDx has become a leading innovative company in
companion diagnostics and the total solution provider for precision
medicine in China.
Taking advantage of the comprehensive
translational platforms including genomics, proteomics, cytomics,
and pathology, MEDx offers our customers the integrated solutions
from biomarker discovery, target validation, molecular testing, and
patient stratification for drug clinical trials, to the IVD/CDx
R&D and commercialization. With a world-class technical team
and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of
world-renowned pharmaceutical companies.
MEDx built up the high-quality system and the
world’s leading StarLIMS system used for laboratory information
management and has been rewarded with many certifications including
China CNAS, ISO17025, and US CAP ISO 13485 etc. MEDx is also the
founding member of China Precision Medicine and Companion Diagnosis
Committee under the Chinese Society of Biotechnology.
To find out more, please
visit www.MEDxTMC.com.
For media queries, contact:
Dr Lynne Trowbridge
VP External Communications
T: +44 (0)7815 167026
E: external.comms@abcam.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024